Revelation Capital Management, LLC has made headlines with its recent filing, revealing its latest investment holdings as of September 30, 2026. This filing is significant as it showcases the firm's strategic investments in the biotechnology sector, particularly in Artiva Biotherapeutics and Obsidian Therapeutics.

Revelation Capital Management, based in Sausalito, California, is an investment firm that specializes in managing assets for various clients. The firm has been active in the market, with its most recent filings indicating a focus on innovative healthcare solutions. The company operates under the SEC's 1934 Act and has a history of reporting its holdings through Form 13F.

The latest filing, accession number 0001104659-26-121312, was submitted on November 2, 2026, and details the firm's investments. According to the filing, Revelation Capital Management has invested approximately $2,131,094 in Artiva Biotherapeutics and $5,881,191 in Obsidian Therapeutics. Both companies are involved in the biotechnology sector, which has seen increased interest from investors due to ongoing advancements in medical treatments and therapies.

The filing indicates that Revelation Capital Management holds 299,311 shares of Artiva Biotherapeutics and 428,346 shares of Obsidian Therapeutics, both classified as common stock. The firm has full investment discretion over these holdings, suggesting a strong belief in the potential of these companies to drive future growth.

This update may impact various stakeholders, including clients of Revelation Capital Management, as well as the broader biotechnology industry. Investors and analysts will likely scrutinize these positions to gauge the firm's outlook on the biotech sector, which is characterized by rapid innovation and substantial market potential.

Looking ahead, the filing does not specify any immediate next steps for Revelation Capital Management. However, it is expected that the firm will continue to monitor its investments closely and may adjust its portfolio in response to market conditions and developments within the companies it has invested in.